Lung Cancer Clinical Trial
First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Summary
The purposes of this study are to determine:
The safety of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin, or docetaxel with carboplatin and any side effects that might be associated with the combination of these drugs.
Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can help participants with non-small cell lung cancer (NSCLC) live longer, compared with the combination of docetaxel and carboplatin.
Whether the combination of enzastaurin plus pemetrexed and carboplatin or pemetrexed and carboplatin can make your tumor smaller or disappear, and for how long, compared with the combination of docetaxel and carboplatin.
The effects of enzastaurin plus pemetrexed with carboplatin, pemetrexed with carboplatin or docetaxel with carboplatin have on your disease related symptoms.
The relation of smoking history and hormone replacement therapy (for women only) may have to your lung cancer treatment results.
The effects of certain genes and proteins in samples of your blood and tumor tissue in order to learn more about NSCLC and how enzastaurin works in the body.
Eligibility Criteria
Inclusion Criteria:
You must have been diagnosed with NSCLC.
You must be able to visit the doctor's office weekly during the active treatment period and as needed during the study follow-up period.
You must be willing and able to swallow capsules.
Your entry labs and medical tests must meet study requirements.
You must be willing to have blood samples drawn and tissue samples obtained for gene and protein testing.
Exclusion Criteria:
You have received radiation within 2 weeks of study enrollment.
You have previously received any anti-cancer drug therapy for NSCLC.
You have an active infection or other serious condition.
You take aspirin or aspirin-like medication regularly and are not able to stop taking them for a few days during each cycle of chemotherapy.
You have recently lost a significant amount of weight.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 4 Locations for this study
Burlington North Carolina, 27215, United States
Chapel Hill North Carolina, 27599, United States
Columbia South Carolina, 29210, United States
Houston Texas, 77060, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.